It’s only fair to share… REMOGLIFLOZIN ETABONATE 5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside, ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxy-oxan-2-yl]methyl carbonate https://clinicaltrials.gov/show/NCT02537470 UNII:TR0QT6QSUL CAS 442201-24-3 189075 BHV-091009 GSK-189075 GSK-189075A KGT-1681 BHV Pharma Kissei (Originator) , GlaxoSmithKline Remogliflozin etabonate Phase II A SGLT-2 antagonist potentially for the treatment of type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity. GSK-189075; GSK-189075A Molecular FormulaC26H38N2O9 Average mass522.588 Remogliflozin etabonate (INN/USAN)[1] …